Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study / Cervantes, Francisco; Ross, David M; Radinoff, Atanas; Palandri, Francesca; Myasnikov, Alexandr; Vannucchi, Alessandro M; Zachee, Pierre; Gisslinger, Heinz; Komatsu, Norio; Foltz, Lynda; Mannelli, Francesco; Passamonti, Francesco; Gilotti, Geralyn; Sadek, Islam; Tiwari, Ranjan; Zor, Evren; Al-Ali, Haifa Kathrin. - In: LEUKEMIA. - ISSN 0887-6924. - ELETTRONICO. - 35:(2021), pp. 3626-3626. [10.1038/s41375-021-01396-x]
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Vannucchi, Alessandro MWriting – Original Draft Preparation
;Mannelli, Francesco;
2021
Abstract
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
